Mark T. Fleming

15.7k citations

125 papers · 6.3k indexed · 2 hit papers · h-index 30

Impact in

Radiological and Ultrasound Technology top 0.2%
- Occupational Health and Safety Research
Medical Laboratory Technology top 0.5%

Papers in ⓘ

Pulmonary and Respiratory Medicine 59
- Prostate Cancer Treatment and Research 45
Oncology 41
- Cancer Immunotherapy and Biomarkers 19
- Cancer Treatment and Pharmacology 14

Co-authors: Howard I. Scher (9 shared papers)Johann S. de Bono (10 shared papers)Karim Fizazi (6 shared papers)Fred Saad (3 shared papers)Neal D. Shore (13 shared papers)Andrew J. Armstrong (5 shared papers)Mary‐Ellen Taplin (3 shared papers)Mohammad Hirmand (2 shared papers)
Journals: Journal of Clinical Oncology (43 papers)Annals of Oncology (8 papers)Sexually Transmitted Diseases (5 papers)Clinical Cancer Research (4 papers)The Journal of Urology (4 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Mark T. Fleming

125 papers receiving 6.0k citations

Hit Papers

align trajectories log scale

Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial 2021 · 183 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2021 The Lancet Oncology
2012 New England Journal of Medicine

Peers

Countries citing papers authored by Mark T. Fleming

Since Specialization

Citations

This map shows the geographic impact of Mark T. Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark T. Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark T. Fleming more than expected).

Fields of papers citing papers by Mark T. Fleming

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark T. Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark T. Fleming. The network helps show where Mark T. Fleming may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark T. Fleming, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark T. Fleming Line = papers co-authored together Mark T. Fleming links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 125 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy New England Journal of Medicine ·Howard I. Scher, Karim Fizazi, Fred Saad, Mary‐Ellen Taplin, Cora N. Sternberg, Kurt Miller, Ronald de Wit, Peter F.A. Mulders, Kim N., Neal D. Shore, Andrew J. Armstrong, Thomas W. Flaig, Aude Fléchon, Paul N. Mainwaring, Mark T. Fleming, John D. Hainsworth, Mohammad Hirmand, Bryan Selby, Lynn Seely, Johann S. de Bono Hit paper breakdown →	2012	3326
2	Measuring safety climate on offshore installations Work & Stress ·Kathryn Mearns, Rhona Flin, Rachale Gordon, Mark T. Fleming	1998	232
3	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial The Lancet Oncology ·Johann S. de Bono, Niven Mehra, Giorgio V. Scagliotti, Elena Castro, Tanya B. Dorff, Adam Stirling, Arnulf Stenzl, Mark T. Fleming, Celestia S. Higano, Fred Saad, Consuelo Buttigliero, Inge M. van Oort, Alexander Laird, Marielena Mata, Hsiang-Chun Chen, Cynthia G. Healy, Akos Czibere, Karim Fizazi Hit paper breakdown →	2021	183
4	Human and organizational factors in offshore safety Work & Stress ·Kathryn Mearns, Rhona Flin, Rachael Gordon, Mark T. Fleming	2001	162
5	Identifying, understanding and overcoming barriers to medication error reporting in hospitals: a focus group study BMJ Quality & Safety ·Nicole R. Hartnell, Neil J. MacKinnon, Ingrid Sketris, Mark T. Fleming	2012	146
6	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer Annals of Oncology ·Guru Sonpavde, В. Б. Матвеев, John M. Burke, J. R. Caton, Mark T. Fleming, Thomas E. Hutson, Matt D. Galsky, William L. Berry, Petr Karlov, Jon Holmlund, Brian Wood, Matthew Brookes, L. Leopold	2011	118
7	Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy Annals of Oncology ·Guru Sonpavde, Phillip Periman, D. M. Bernold, Douglas Weckstein, Mark T. Fleming, Matthew D. Galsky, William R. Berry, Feng Zhan, Kristi A. Boehm, Lina Asmar, Thomas E. Hutson	2009	115
8	Description of the development and validation of the Canadian Paediatric Trigger Tool BMJ Quality & Safety ·Anne Matlow, Catherine Cronin, Virginia Flintoft, Cheri Nijssen‐Jordan, Mark T. Fleming, Barbara Brady-Fryer, Mary-Ann Hiltz, Elaine Orrbine, G. Ross Baker	2011	66
9	Risk perception by offshore workers on UK oil and gas platforms Safety Science ·Rhona Flin, Kathryn Mearns, Rachael Gordon, Mark T. Fleming	1996	65
10	Patient Safety Culture Measurement and Improvement: A "How To" Guide Healthcare Quarterly ·Mark T. Fleming	2005	63
11	Patient Safety Culture Improvement Tool: Development and Guidelines for Use Healthcare Quarterly ·Mark T. Fleming, Natasha Wentzell	2008	58
12	Evaluation of psychosocial and organizational factors in offshore safety: a comparative study Journal of Risk Research ·Kathryn Mearns, Torbjørn Rundmo, Rhona Flin, Rachael Gordon, Mark T. Fleming	2004	57
13	Advancing Measurement of Patient Safety Culture Health Services Research ·Liane Ginsburg, Debra Gilin, Deborah Tregunno, Peter Norton, W. Ward Flemons, Mark T. Fleming	2008	56
14	Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients Clinical Cancer Research ·Arti Hurria, Mark T. Fleming, Sharyn D. Baker, Wm. Kevin Kelly, Katie Cutchall, Katherine S. Panageas, James F. Caravelli, Henry Yeung, Mark G. Kris, Jorge Gómez, Vincent A. Miller, Gabriella D’Andrea, Howard I. Scher, Larry Norton, Clifford A. Hudis	2006	56
15	Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer The Prostate ·Daniel P. Petrylak, Philip W. Kantoff, Nicholas J. Vogelzang, Anthony Mega, Mark T. Fleming, Joe Stephenson, Richard C. Frank, Neal D. Shore, Robert Dreicer, Edward F. McClay, William R. Berry, Manish Agarwal, Vincent A. DiPippo, Yakov Rotshteyn, Nancy Stambler, William C. Olson, Stephen Morris, Robert J. Israel	2019	55
16	First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). Journal of Clinical Oncology ·Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park, JesÃos GarcÃa-Donas, Robert Huddart, Earle F. Burgess, Mark T. Fleming, Arash Rezazadeh, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Durán, Scott T. Tagawa, Anne O’Hagan, Anjali Narayan Avadhani, Bob Zhong, Peter De Porre, Yohann Loriot, (unknown)	2018	54
17	Cognitive elements in clinical decision-making Advances in Health Sciences Education ·Bruce C. Dunphy, Robert Cantwell, Sid Bourke, Mark T. Fleming, Bruce R. Smith, K.S. Joseph, Stacey L. Dunphy	2009	53
18	A Phase II Trial of Temsirolimus in Men With Castration-Resistant Metastatic Prostate Cancer Clinical Genitourinary Cancer ·Andrew J. Armstrong, Tong Shen, Susan Halabi, Gabor Kemeny, Rhonda L. Bitting, Patricia A. Kartcheske, Elizabeth Embree, Karla K. Morris, Carolyn Winters, Tracy A. Jaffe, Mark T. Fleming, Daniel J. George	2013	53
19	Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors Investigational New Drugs ·Matthew D. Galsky, Daniel D. Von Hoff, Marcus A. Neubauer, Thomas Anderson, Mark T. Fleming, Yasir M. Nagarwala, Janine Mahoney, Dawn Midwinter, Linda Vocila, Tal Zaks	2010	52
20	Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials Nature Clinical Practice Oncology ·Mark T. Fleming, Michael J. Morris, Glenn Heller, Howard I. Scher	2006	49

About Mark T. Fleming

Mark T. Fleming is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Surgery, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 125 papers that have together received 6.3k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (45 papers), Bladder and Urothelial Cancer Treatments (31 papers), Radiopharmaceutical Chemistry and Applications (28 papers), Cancer Immunotherapy and Biomarkers (19 papers), Urinary and Genital Oncology Studies (15 papers), Occupational Health and Safety Research (15 papers), Cancer Treatment and Pharmacology (14 papers) and Risk and Safety Analysis (12 papers). The work is most often cited by research in Radiological and Ultrasound Technology (727 citations), Medical Laboratory Technology (178 citations), Pulmonary and Respiratory Medicine (3.8k citations), Cancer Research (1.2k citations) and Statistics, Probability and Uncertainty (527 citations). Mark T. Fleming has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Howard I. Scher, Johann S. de Bono, Karim Fizazi, Fred Saad, Neal D. Shore, Andrew J. Armstrong, Mary‐Ellen Taplin, Mohammad Hirmand, Kim N. and Cora N. Sternberg. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Sexually Transmitted Diseases, Clinical Cancer Research and The Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact